LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab …
WEBPreliminary ada plus pembrolizumab (pembro) data showed a manageable safety profile and encouraging clinical activity. We report updated efficacy and safety in more patients (pts) treated with ada plus pembro in KRYSTAL-7 (NCT04613596).
1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus ...
WEBThe phase 3 portion of the KRYSTAL-7 study is a global, open-label, randomized trial comparing the efficacy and safety of first-line adagrasib (400 mg BID until disease progression) plus pembrolizumab (200 mg Q3W up to 35 cycles) versus pembrolizumab alone (200 mg Q3W up to 35 cycles) in patients with unresectable, locally advanced or metastatic KRAS G12C-mutated NSCLC (squamous or nonsquamous ...
Adagrasib Added to Pembrolizumab Safely, Effectively Treats
WEBOct 20, 2023 · The results of the KRYSTAL-7 phase 2 trial found adding adagrasib to pembrolizumab in patients with advanced, unresectable, or metastatic NSCLC with KRASG12C mutation showed “encouraging ...
Adagrasib in Non–Small-Cell Lung Cancer Harboring a
WEBJun 3, 2022 · Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in...
Mirati Presents Late-Breaking Results Evaluating the Combination …
WEBOct 17, 2023 · In patients with PD-L1 TPS ≥50%, adagrasib and pembrolizumab demonstrated an overall response rate (ORR) of 63% and disease control rate (DCR) of 84% and promising early signs of durability.
Frontline Promise for Adagrasib-Pembrolizumab Combination
WEBFeb 6, 2023 · Two trials offer early evidence that adagrasib plus pembrolizumab is a safe and effective regimen for patients with newly diagnosed non-small cell lung cancer harboring a KRASG12C mutation. The overall response rate in one trial was 49%, and in the other it was 57%.
KRYSTAL-12 Shows PFS Benefit With Adagrasib Over Docetaxel in ...
WEBJun 1, 2024 · Key Points: In the randomized phase 3 KRYSTAL-12 trial, adagrasib demonstrated a significant efficacy benefit over docetaxel, including improvements in progression-free survival (PFS) and objective response rate (ORR), in patients with previously-treated advanced KRASG12C -mutated non–small cell lung cancer (NSCLC).
Positive results for combination in KRAS G12C-mutated NSCLC
WEBDec 7, 2022 · KRAS G12C inhibition with adagrasib plus pembrolizumab in KRAS G12C-mutated non-small-cell lung cancer (NSCLC) may be a beneficial first-line approach, according to a presentation at ESMO Immuno-Oncology Congress 2022 (Geneva, 7–9 December) (LBA4).
KRYSTAL-7: Efficacy and Safety of Adagrasib with Pembrolizumab …
WEBDec 15, 2023 · KRYSTAL-7 is a study exploring the efficacy of adding adagrasib to first-line pembrolizumab in patient with NSCLC with varying PD-L1 expression levels, showing promising response rates and progression-free survival, but …
Mirati Therapeutics Presents Late-Breaking Results Evaluating ...
WEBDec 5, 2022 · Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRAS G12C...
- Some results have been removed